Marimed (MRMD) Receivables (2011 - 2026)

Marimed (MRMD) has 15 years of Receivables data on file, last reported at $9.4 million in Q1 2026.

• On a quarterly basis, Receivables rose 2.93% year-over-year to $9.4 million in Q1 2026; TTM through Mar 2026 was $9.4 million, a 2.93% increase from a year earlier, with the FY2025 full-year figure at $9.4 million, up 5.22% from the prior year.
• Receivables for Q1 2026 stood at $9.4 million, up from $9.1 million in the prior quarter.
• Over the last five years, Receivables for MRMD reached as high as $9.4 million in Q1 2026 and fell as low as $3.4 million in Q1 2022.
• Historically, Receivables has averaged $7.2 million across 5 years, with a median of $7.6 million in 2024.
• On a YoY basis, Receivables climbed as much as 447.56% in 2022 and fell as far as 53.69% in 2022.
• Year by year, Receivables stood at $8.7 million in 2022, then retreated by 17.84% to $7.2 million in 2023, then gained by 21.49% to $8.7 million in 2024, then increased by 4.48% to $9.1 million in 2025, then climbed by 3.57% to $9.4 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $9.4 million in Q1 2026, $9.1 million in Q4 2025, and $8.0 million in Q3 2025.